Benjamin Garmezy

4PUBLICATIONS
36CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cheminformatics and quantitative structure-activity relationshipsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|May 16, 2026
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.

|Jul 10, 2025
Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor.

Benjamin Garmezy, Joseph E Grossman, Jennifer Buell

|Apr 11, 2024
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.

Benjamin Garmezy, Mitesh J Borad, Rastilav Bahleda

|Feb 02, 2022
Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers.

Benjamin Garmezy, Jinesh Gheeya, Heather Y Lin

Pageof 1

Frequent Collaborators

1 joint publications

Jinesh Gheeya

1 joint publications

Heather Y Lin

1 joint publications

Taebeom Kim

1 joint publications

Xianli Jiang